Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nile Therapeutics, a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, has appointed Michael Bristow to its scientific advisory board.
Subscribe to our email newsletter
In his role, Bristow will be overseeing the development of CD-NP, a dual natriuretic peptide receptor agonist in development for the treatment of acute decompensated heart failure.
Nile CEO Joshua Kazam said that they are extremely pleased to welcome Bristow to advisory board.
“We believe that his depth of knowledge in the field of heart failure and his breadth of experience in drug development and commercialization will help us achieve the full potential of CD-NP and our natriuretic peptide program,” Kazam said.